Study finds, Biomarkers as Efficient therapy monitoring for
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Bone turnover biochemical markers (BTMs) such as bone alkaline phosphatase (bALP), procollagen type I N propeptide (PINP), serum cross-linked C-telopeptides of type I collagen (bCTx), and urinary cross-linked N-telopeptides of type I collagen (NTx) are widely used for therapy monitoring in osteoporotic patients. The aim of this study was to see whether BTMs could be used for therapy monitoring.

Researchers looked for randomized clinical trials (RCTs) that compared two or more pharmacological therapies for postmenopausal osteoporosis. Only studies that recorded the value of bALP, PINP, bCTx, and NTx at the most recent follow-up were included in the analysis. The researchers used a multivariate study to see if there was a connection between these biomarkers and clinical results and the incidence of adverse effects in postmenopausal osteoporosis patients.

Results:
--A total of 16 RCTs were included. The median age was 67 years, and the median BMI 25.4 kg/m2. The median vertebral BMD was 0.82, hip BMD 0.79, and femur BMD 0.64 g/cm2.

--The ANOVA test found optimal within-group variance concerning mean age, body mass index, and BMD. Greater bALP was associated with lower femoral BMD.

--Greater NTx was associated with a greater number of non-vertebral fractures.

--Greater NTx was associated with greater rate of therapy discontinuation. No other statistically significant associations were detected.

Conclusively, this analysis supports the adoption of BTMs in therapy monitoring of osteoporotic patients.

Source: https://josr-online.biomedcentral.com/articles/10.1186/s13018-021-02474-7
Like
Comment
Share